XRTX XORTX Therapeutics Inc. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1729214 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2021*2021-12-31 | FY2020*2020-12-31 | FY2019*2019-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | 853,124 | 277,455 | 39,897 |
| SG&A expense | 176,099 | 9,516 | 17,344 |
| Pretax income | -3.65M | -1.40M | -565,965 |
| Net income | -1.65M | -1.28M | -629,576 |
| EPS (diluted) | — | — | — |
| Balance sheet | |||
| Cash & equivalents | 18.85M | 171,271 | 58,614 |
| Receivables | 51,539 | 14,351 | — |
| Current assets | 20.17M | 2.06M | — |
| Total assets | 22.04M | 2.29M | — |
| Current liabilities | 700,999 | 1.03M | — |
| Total liabilities | 5.30M | 1.03M | — |
| Shareholders' equity | 16.74M | 1.26M | -211,721 |
| Shares outstanding | 1.79M | — | — |
| Cash flow statement | |||
| Operating cash flow | -6.06M | -728,401 | -249,580 |
| Financing cash flow | 24.46M | 855,408 | 55,212 |
| Depreciation & amortization | 17,882 | 20,439 | 19,900 |
| Stock-based compensation | 499,158 | 293,443 | 26,317 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.